<- Go Home
Bavarian Nordic A/S
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Market Cap
DKK 14.6B
Volume
357.0K
Cash and Equivalents
DKK 692.9M
EBITDA
DKK 1.4B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
DKK 2.9B
Profit Margin
48.11%
52 Week High
DKK 244.80
52 Week Low
DKK 166.70
Dividend
N/A
Price / Book Value
1.16
Price / Earnings
12.84
Price / Tangible Book Value
2.16
Enterprise Value
DKK 12.4B
Enterprise Value / EBITDA
8.70
Operating Income
DKK 769.1M
Return on Equity
9.68%
Return on Assets
3.48
Cash and Short Term Investments
DKK 2.3B
Debt
DKK 139.3M
Equity
DKK 12.7B
Revenue
DKK 6.0B
Unlevered FCF
-DKK 501.8M
Sector
Biotechnology
Category
N/A